. 2022 Oct 5;2022:9385459. doi: 10.1155/2022/9385459

Table 1.

Comparison of craniocervical flexion test and 8 domains of SF 36 within the experimental group.

Variable	—	Interquartile range	Mean rank^a	Chi-square (X²), p value^a	Post hoc analysis	Z score^b	p value^b
Craniocervical flexion (mmHg)	Base line	21 (20 to 24)	1.07	78.28, p < 0.05	Pre and midtreatment	-5.56	<0.017
	After 2^nd week	24 (24 to 26)	2.10		Mid and posttreatment	-5.15	<0.017
	After 4^th week	26 (24 to 28)	2.83		Pre and posttreatment	-5.78	<0.017
Physical functioning–SF36	Baseline	35 (20 to 55)	1.15	73.92, p < 0.05	Pre and midtreatment	-4.59	<0.017
	After 2^nd week	57 (35 to 70)	1.94		Mid and posttreatment	-5.43	<0.017
	After 4^th week	75 (60 to 85)	2.91		Pre and posttreatment	-5.46	<0.017
Role limitation due to physical health–SF36	Baseline	0 (0 to 25)	1.28	66.72. p < 0.05	Pre and midtreatment	-4.38	<0.017
	After 2^nd week	25 (25 to 50)	1.91		Mid and posttreatment	-5.01	<0.017
	After 4^th week	62.5 (50 to 100)	2.81		Pre and posttreatment	-5.49	<0.017
Role limitation due to emotional problem–SF36	Baseline	0 (0 to 33.3)	1.59	36.20, p < 0.05	Pre and midtreatment	-2.68	<0.017
	After 2^nd week	33.3 (0 to 66.7)	1.89		Mid and posttreatment	-3.72	<0.017
	After 4^th week	66.7 (33.3 to 100)	2.52		Pre and posttreatment	-4.49	<0.017
Energy/fatigue–SF36	Baseline	45 (35 to 50)	1.18	61.82, p < 0.05	Pre and midtreatment	-4.56	<0.017
	After 2^nd week	55 (45 to 60)	2.03		Mid and posttreatment	-4.95	<0.017
	After 4^th week	60 (50 to 75)	2.78		Pre and posttreatment	-5.21	<0.017
Emotional wellbeing–SF36	Baseline	52 (44 to 60)	1.45	36.96, p < 0.05	Pre and midtreatment	-3.83	<0.017
	After 2^nd week	56 (52 to 64)	1.94		Mid and posttreatment	-4.30	<0.017
	After 4th week	66 (53 to 75)	2.60		Pre and posttreatment	-4.61	<0.017
Social functioning–SF36	Baseline	43.75 (37.5 to 62.5)	1.38	53.26, p < 0.05	Pre and midtreatment	-3.91	<0.017
	After 2^nd week	62.50 (50 to 75)	1.89		Mid and posttreatment	-5.06	<0.017
	After 4^th week	75 (62.5 to 87.5)	2.74		Pre and posttreatment	-4.95	<0.017
Pain–SF36	Baseline	45 (43.1 to 45)	1.34	61.10, p < 0.05	Pre and midtreatment	-4.26	<0.017
	After 2^nd week	55 (45 to 66.87)	1.92		Mid and posttreatment	-4.97	<0.017
	After 4^th week	67.5 (55 to 86.87)	2.74		Pre and posttreatment	-5.17	<0.017
General health–SF36	Baseline	40 (35 to 55)	1.34	63.18, p < 0.05	Pre and midtreatment	-3.79	<0.017
	After 2^nd week	52.5 (40 to 65)	1.76		Mid and posttreatment	-5.54	<0.017
	After 4^th week	75 (50 to 83.75)	2.90		Pre and posttreatment	-5.56	<0.017

^a Friedman test statistics, ^b post hoc analysis.